Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Bladder Cancer

Bladder Cancer

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Bladder Cancer

168 trials tracked for Bladder Cancer: 20 in phase 3 or 4 and 9 with published results. The most-cited published study has 1428 citations.

168Trials tracked
20Phase 3 & 4
0Recruiting
9With published results
Phase distribution
Phase 4 4 Phase 3 16 Phase 2 104 Phase 1 15 Other / NA 29
  1. Phase 3 A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211] Completed · 1,428 cited
  2. Phase 3 A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) Completed · 1,185 cited
  3. Phase 3 ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Completed · 449 cited
  4. Phase 3 S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Completed · 237 cited
  5. Phase 4 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed · 112 cited
  6. Phase 3 A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting Completed · 109 cited
Show 44 more trials
  1. Phase 3 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Completed · 58 cited
  2. Phase 3 The Bladder Instillation Comparison Study Completed · 39 cited
  3. Phase 4 Comparison of Obturator Nerve Blockade and Neuromuscular Blockade Completed · 10 cited
  4. Phase 4 Investigation of Sugammadex in Outpatient Urological Procedures Completed
  5. Phase 4 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed
  6. Phase 3 Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611) Completed
  7. Phase 3 Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612) Completed
  8. Phase 3 Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy Completed
  9. Phase 3 Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG Completed
  10. Phase 3 A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer Completed
  11. Phase 3 Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) Completed
  12. Phase 3 Comparative Study of Hexvix Blue Light Cystoscopy and White Light Cystoscopy in the Detection of Bladder Cancer Completed
  13. Phase 3 A Randomized, Comparative Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder Cancer Completed
  14. Phase 3 Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy Completed
  15. Phase 2 Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer Completed
  16. Phase 2 RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder Completed
  17. Phase 2 Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo Completed
  18. Phase 2 Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer Completed
  19. Phase 2 Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer Completed
  20. Phase 2 A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers Completed
  21. Phase 2 Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer Completed
  22. Phase 2 Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer Completed
  23. Phase 2 Bupropion in Helping Adults Stop Smoking Completed
  24. Phase 2 Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. Completed
  25. Phase 2 Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer Completed
  26. Phase 2 Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract Completed
  27. Phase 2 Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer Completed
  28. Phase 2 Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477) Completed
  29. Phase 2 Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma Completed
  30. Phase 2 Evaluation of NanoDoce® in Participants With Urothelial Carcinoma Completed
  31. Phase 2 Sunitinib in Treating Patients With Locally Advanced Bladder Cancer Completed
  32. Phase 2 Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer Completed
  33. Phase 2 Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer Completed
  34. Phase 2 Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery Completed
  35. Phase 2 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Completed
  36. Phase 2 Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer Completed
  37. Phase 2 Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer Completed
  38. Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma Completed
  39. Phase 2 2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer Completed
  40. Phase 2 Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer Completed
  41. Phase 2 Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma Completed
  42. Phase 2 Intravesicular Abraxane for Treatment-Refractory Bladder Cancer Completed
  43. Phase 2 Study of Tremelimumab in Patients With Advanced Solid Tumors Completed
  44. Phase 2 A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer Completed

Showing the 50 most-cited and recently-updated of 168 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Bladder Cancer: what the trials found

Enfortumab Vedotin demonstrated superior efficacy compared to the control in patients with bladder cancer, showing a statistically significant improvement in Overall Survival (OS) (12.88 vs 8.97; p=0.00142), Progression Free Survival (PFS1) (5.55 vs 3.71; p<0.00001), and Overall Response Rate (ORR) (40.6% vs 17.9%; p<0.001) 13.

Gemcitabine hydrochloride was associated with a significantly lower disease recurrence rate compared to the control (27.86% vs 40%; p=0.01), though no significant difference was found in the rate of progression to muscle invasive disease at 4 years (2.49% vs 4.39%; p=0.23) 15.

Hexaminolevulinate hydrochloride, utilized in both a Phase 3 study 19 and a trial evaluating blue light cystoscopy 16, showed that Blue Light Cystoscopy with Cysview significantly increased the detection of histologically confirmed malignancies (13%) and Carcinoma in Situ (CIS) lesions (9%) compared to white light cystoscopy (p<0.0001) 16.

Bevacizumab did not show a statistically significant difference in Overall Survival between groups (14.5 vs 14.3; p=0.1707) 17. Vicinium demonstrated a Complete Response Rate of 39% at 3 months, which decreased over subsequent follow-up periods up to 24 months (13%) 22.

Recent results — preliminary, needs further review

  • Cabazitaxel + Cisplatin chemotherapy showed a 5-year Progression Free Survival after cystectomy of 61.5% and an Overall Survival of 65.4% 2.
  • The Cancer Resource Information Support (CRIS) did not show statistically significant differences in patient quality of life, caregiver quality of life, or infection rates 6.
  • Studies are ongoing/recent for combinations including IO102-IO103 with pembrolizumab 1, L-NMMA 3, and 89Zr-TLX250 4.

For the clinician treating this condition

  • Enfortumab Vedotin is associated with superior OS, PFS, and ORR compared to standard controls in bladder cancer patients 13.
  • Gemcitabine hydrochloride significantly reduces the rate of disease recurrence 15.
  • Blue Light Cystoscopy with Cysview (utilizing Hexaminolevulinate) provides a statistically significant advantage in detecting malignancies and CIS lesions over white light cystoscopy 16.

AI synthesis of 11 cited trials, updated Jun 21, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Audit plus peer comparison improved documentation of tumour features and resection completeness in non-muscle-invasive bladder cancer surgery
Urology RCT
Audit plus peer comparison improved documentation of tumour features and resection completeness in non-muscle-invasive bladder cancer surgery Audit and feedback improved documentation of bladder cancer surgery details in a large trial
This cluster randomised controlled trial involved 14,915 patients undergoing transurethral resection of bladder tumour surgery across 201 si…
This large study examined whether adding peer comparison and education to standard audits changed how bladder cancer surgery was performed.
Apr 6, 2026

Questions about Bladder Cancer

Can machine learning help predict risks before surgery for bladder cancer?

Yes, machine learning models using CT scans and clinical data can predict survival and metastasis risk before bladder cancer surgery, with some models achieving high accuracy.

Full answer →
Does adding gemcitabine improve survival for muscle-invasive bladder cancer patients?

Yes, adding gemcitabine to cisplatin-based chemotherapy improves survival for muscle-invasive bladder cancer patients, as shown in the NIAGARA trial.

Full answer →
Does adding mitomycin to BCG help high-risk non-muscle-invasive bladder cancer?

No, adding mitomycin to BCG did not improve disease-free survival in high-risk NMIBC patients in a large randomized trial.

Full answer →
Is cisplatin better than carboplatin for surviving advanced bladder cancer?

Yes, cisplatin-based chemotherapy is associated with better overall survival than carboplatin for advanced bladder cancer, but carboplatin is used when patients cannot tolerate cisplatin due to kidney problems or other health issues.

Full answer →